We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
Cap. Flow
+$24.2M
Cap. Flow %
3.06%
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$35.2M
2
UTHR icon
United Therapeutics
UTHR
+$14.5M
3
ABVX
Abivax
ABVX
+$9.93M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$9.38M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.02M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$10.4M
2
TERN
Terns Pharmaceuticals
TERN
+$9.58M
3
TGTX icon
TG Therapeutics
TGTX
+$8.47M
4
INCY icon
Incyte
INCY
+$7.74M
5
JNJ icon
Johnson & Johnson
JNJ
+$7.4M

Sector Composition

Rank Sector Weight
1 Miscellaneous 66.57%
2 Healthcare 33.4%
3 Consumer Discretionary 0.02%
4 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVS icon
76
CALL
Corvus Pharmaceuticals
CRVS
$1.21B
$1.99M 0.25%
133,400
+27,100
+25% +$376K
CTNM
77
Contineum Therapeutics
CTNM
$628M
$1.96M 0.25%
+119,733
New +$1.57M
BCYC
78
Bicycle Therapeutics
BCYC
$301M
$1.96M 0.25%
462,724
-13,700
-3% -$62.8K
GLUE icon
79
Monte Rosa Therapeutics
GLUE
$1.18B
$1.9M 0.24%
78,391
-108,916
-58% -$2.06M
CLDX icon
80
CALL
Celldex Therapeutics
CLDX
$3.12B
$1.89M 0.24%
+50,900
New +$1.64M
VRDN icon
81
Viridian Therapeutics
VRDN
$2.6B
$1.84M 0.23%
+100,000
New +$1.61M
MGNX icon
82
MacroGenics
MGNX
$280M
$1.73M 0.22%
374,403
-225,597
-38% -$853K
PRQR icon
83
ProQR Therapeutics
PRQR
$292M
$1.72M 0.22%
926,016
+745,933
+414% +$1.23M
ADMA icon
84
CALL
ADMA Biologics
ADMA
$2.15B
$1.67M 0.21%
+200,000
New +$1.82M
SPRB
85
Spruce Biosciences
SPRB
$166M
$1.62M 0.2%
30,000
+20,000
+200% +$1.12M
ARDX icon
86
Ardelyx
ARDX
$976M
$1.55M 0.2%
+303,025
New +$1.85M
CUE icon
87
Cue Biopharma
CUE
$199M
$1.53M 0.19%
48,369
+43,969
+999% +$994K
MLYS icon
88
Mineralys Therapeutics
MLYS
$2.49B
$1.52M 0.19%
56,347
+30,000
+114% +$823K
EYPT icon
89
CALL
EyePoint Inc
EYPT
$395M
$1.52M 0.19%
106,300
– –
SLS icon
90
PUT
SELLAS Life Sciences
SLS
$2.8B
$1.48M 0.19%
+100,000
New +$690K
PRTA icon
91
Prothena Corp
PRTA
$504M
$1.46M 0.18%
+149,482
New +$1.48M
VYGR icon
92
Voyager Therapeutics
VYGR
$216M
$1.45M 0.18%
413,642
-10,000
-2% -$37.9K
UNCY icon
93
Unicycive Therapeutics
UNCY
$144M
$1.42M 0.18%
303,676
+197,593
+186% +$1.46M
PHAT icon
94
Phathom Pharmaceuticals
PHAT
$769M
$1.41M 0.18%
129,950
+75,300
+138% +$859K
EOLS icon
95
CALL
Evolus
EOLS
$614M
$1.39M 0.18%
200,000
+74,800
+60% +$442K
SYRE icon
96
Spyre Therapeutics
SYRE
$7.85B
$1.33M 0.17%
+15,000
New +$1.09M
HELP
97
Cybin Inc
HELP
$893M
$1.32M 0.17%
+200,000
New +$1M
CRMD icon
98
PUT
CorMedix
CRMD
$657M
$1.31M 0.17%
167,500
– –
EDIT icon
99
CALL
Editas Medicine
EDIT
$496M
$1.3M 0.16%
+400,000
New +$1.17M
EQ icon
100
Equillium
EQ
$141M
$1.28M 0.16%
400,282
-33,562
-8% -$80.4K
2 3
4
5 6

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.

By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.

  • Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
  • Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
  • Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
  • Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
  • Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
  • Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
  • Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.